

**These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling.**

**Drug Details**

Company Name	Business Partner	Drug Name	Generic Name	Unique ID	Studied Indications or Disease	Phase
Abbott Laboratories		Zemplar Capsules	Paricalcitol	2001019	Hyperparathyroidism, Secondary	Phase III

**Clinical Study Summary**  
 Protocol No. 2001019: A Phase III, Prospective, Randomized, Placebo-controlled, Double-blind, Multi-center Study to Determine the Safety and Efficacy of Zemplar Capsule (Dosed three times weekly) in Reducing Elevated Serum Intact Parathyroid Hormone Levels in Subjects with Chronic Kidney Disease.

Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. *Kidney International* 2005; 68: 2823-2828.

Coyne D, Acharya M, Qiu P, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. *American Journal of Kidney Diseases* 2006; 47(2):263-276.

Abboud H, Coyne D, Smolenski O, et al. A Comparison of Dosing Regimens of Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in CKD Stages 3 and 4. *Am J Nephrol* 2006;26:105-114.

Abbott Laboratories (Abbott) will use reasonable efforts to include accurate and up-to-date information, consistent with Abbott policies and procedures, on the ClinicalStudyResults.org web site. However, because, among other reasons, the status of studies often changes, Abbott can make no, and makes no, warranties or representations of any kind as to the currency or completeness of the information contained therein. Persons accessing and using information posted by Abbott on the ClinicalStudyResults.org web site do so at their own risk. Abbott disclaims all warranties, express or implied, including warranties of merchantability of fitness for a particular purpose. Abbott shall not be liable for any damages, including without limitation, direct,

incidental, consequential, indirect or punitive damages, arising out of access to, use of, or inability to use information posted by Abbott on the ClinicalStudyResults.org web site, or any errors or omissions in the content thereof.

Company  
Study

No document provided.